Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Trial details
- Registry ID
- NCT07562152
- Drugs studied
- Atebimetinib, GnP, mGnP
TrialRedline tracks 1 clinical trial sponsored by Immuneering Corporation: 1 Phase 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07562152 | Atebimetinib, GnP, mGnP | Recruiting | 2028-06Estimated |
Names as written in the registry records.
NCT07562152 · Immuneering Corporation
Before: 510 participants (planned). After: 570 participants (planned).